EGFR and non-small cell lung carcinoma: ANEAS, a randomized, double-blind, phase-III trial, evaluated the efficacy and safety of aumolertinib compared with gefitinib as a first-line treatment of locally advanced or metastatic EGFR-mutated NSCLC.